web analytics
-0.8 C
Munich
Saturday, November 26, 2022

Todays Equity Focus is Cannabis Science Inc (OTCMKTS:CBIS)

Cannabis Science Inc (OTCMKTS:CBIS) has been moving up steadily in recent days on heavy trading volume. The stock is one of the original pot stocks on the OTC with a long history of huge moves every time the sector moves up.

Investors have been buying up pot stocks lately and it’s easy to see why; Four western US states — Alaska, Colorado, Oregon, Washington as well as the nation’s capital Washington D.C. have legalized marijuana for recreational use. An additional 19 states have legalized marijuana for medical use. 2015 was an epic year for the industry; Colorado earned $135 million in taxes and licensing fees on nearly $1 billion in pot sales and the state of Washington took in $70 million on statewide pot revenue totaling $257 million.

Cannabis Science Inc (OTCMKTS:CBIS) works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness.

CBIS initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Several years ago CBIS made a number of acquisitions in the cannabis sector that currently drive future growth. CBIS 2 most important drugs in development are:

The CS-S/BCC-1 drug program was launched in 2011 due to the “apparent success in 4 skin cancer patients who have self-administered cannabinoid based extracts topically to their skin cancers. These patients have experienced shrinking and apparent eradication of their skin cancer lesions.”

The drug CS-TATI-1 aims to target patients with drug-resistant HIV strains. The earliest article I could find relating to the launch of this program was in June 5, 2012, where the company loosely described a mission to “explore the commercial development of Phyto cannabinoid-based therapeutics for drug resistant HIV infection.”

To Find out the inside Scoop on CBIS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Back in March CBIS commented on the recent success of GW Pharmaceuticals in their phase three testing of a CBD-based product designed to treat patients with a rare form of epilepsy.

The successful trials in Europe help pave the way for companies like Cannabis Science to move forward with their own testing in Europe and in the United States. It will also allow for a quicker regulatory process due to more research being made available for regulators and more experience with these types of treatments.

CBIS is working diligently to continue testing and providing limited rollouts for its own CBD-based treatment products in California at the moment. On the heels of GW Pharmaceuticals’ success, the company is more confident than ever in its planned wide-scale rollout, which will include a wider array of near term clinical drug development programs in California, possibly Washington, and the Netherlands.

On May 4 CBIS said it is pleased to publicly applaud the Drug Enforcement Agency (DEA) for their latest decision to green light clinical trials on the effectiveness of smoked marijuana as a treatment option for post-traumatic stress disorder, proposed Harborside resolution, and the re-scheduling for mass access to expanded treatments. These recent moves by the DEA seem to be signaling the signs of changing times, the right Industry at the right time.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $13 million market valuation CBIS has little assets or revenues and rising short term debt that has resulted in dilution over the years. But CBIS is an exciting story developing in small caps; the Company is specializing in the development of cannabis-based medicines and has a number of new exciting initiatives in the booming pot sector. CBIS is currently testing and providing limited rollouts for its own CBD-based treatment products in California at the moment. The news from GW is a game changer for all pot stocks especially CBIS with several of its own irons in the oven as it proves that cannabinoids can produce compelling and clinical important data and represent a highly promising new class of medications. CBIS is one of the original pot stocks with a long history of making spectacular 2000% plus moves that knows how to get its story into the national media so this is a great place to be when pot stocks heat up. We will be updating on CBIS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CBIS.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in CBIS either long or short and we have not been compensated for this article.

More articles

2 COMMENTS

  1. Hey Carrie,
    Nice article except for the fact that you failed to mention this investor friendly information about CBIS partnering with Jimi’s Meds, a company founded by Leon Hendrix, brother of the late Jimi Hendrix.
    Wouldn’t you agree Carrie that this information is very important and should be shared with your readers?

    Read more here… http://www.jimismeds.com/

    http://purplehazeproperties.com/cbis-purple-haze-properties-launch-jimis-meds-ecommerce-website-powered-by-cannabis-science/

    Keep on doin’ what you do Carrie,
    Thanks!
    Bob

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.